MPH Health Care AG successfully places 927,755 shares in M1 Kliniken AG at EUR 17.50 per share and generates gross proceeds of approximately EUR 16 million

MPH Health Care AG

/ Key word(s): Disposal

MPH Health Care AG successfully places 927,755 shares in M1 Kliniken AG at EUR 17.50 per share and generates gross proceeds of approximately EUR 16 million

19.11.2026 / 21:53 CET/CEST

The issuer is solely responsible for the content of this announcement.


MPH Health Care AG successfully places 927,755 shares in M1 Kliniken AG at EUR 17.50 per share and generates gross proceeds of approximately EUR 16 million

The issuer is solely responsible for the content of this announcement.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION COULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PUBLICATION.
 

  • MPH Health Care AG (“MPH”) has successfully placed 927,755 existing shares in M1 Kliniken AG (“M1”), representing approximately 5 per cent of the issued share capital, with institutional investors by way of an accelerated bookbuilding offering
  • The placement price was set at EUR 17.50 per share; gross proceeds to MPH amount to approximately EUR 16 million
  • Following the settlement of the placement, MPH’s shareholding in M1 will decrease from approximately 66 per cent to approximately 61 per cent; MPH remains the majority shareholder

Berlin, 19 November 2026 – MPH Health Care AG (ISIN: DE000A289V03; “MPH”) has successfully completed the placement, announced on 19 November 2026, of 927,755  existing shares in M1 Kliniken AG (ISIN: DE000A0STSQ8; “M1”) with institutional investors by way of an accelerated bookbuilding offering.
The shares were placed at a price of EUR 17.50 per share. This results in gross proceeds to MPH of approximately EUR 16 million. Following settlement of the transaction, MPH will continue to hold approximately 61 per cent of the issued share capital of M1.
“With the successful placement, we are increasing the free float of M1 and creating the conditions for a broader institutional shareholder base. At the same time, our continued majority shareholding underlines our long-term commitment to M1 and to the further development of the company.”
Patrick Brenske, CEO of MPH Health Care AG

Transaction details

  • The placed offer shares have full dividend entitlement for the financial year 2026
  • A three-month lock-up applies to MPH’s M1 shares remaining after the placement, subject to customary exceptions.
  • Trade Date is expected to be scheduled for 20 November 2026 and Settlement Date for 24 November 2026.
  • Cantor acted as Sole Global Coordinator and Sole Bookrunner for the placement.

About MPH Health Care AG
MPH Health Care AG is a listed investment holding company headquartered in Berlin. Its focus is on the development and long-term value creation of equity investments, particularly in growth segments of the healthcare market. M1 Kliniken AG is MPH’s strategic core holding.

Investor Relations
MPH Health Care AG
Grünauer Straße 5
12557 Berlin
ir@mph-ag.de

Important Notice:
This announcement may not be released, published or distributed, directly or indirectly, in the United States of America (including its territories and possessions), Australia, Canada, Japan, South Africa or any other jurisdiction where such publication could be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons who are in possession of this announcement or other information referred to herein should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.
This announcement does not constitute an offer of, or a solicitation of an offer to purchase, securities of M1 Kliniken AG or of any of its subsidiaries in the United States of America, Germany or any other jurisdiction. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, an offer in any jurisdiction. The securities offered are not and have not been registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act. No public offering of securities is being made in the United States.
In member states of the European Economic Area, the placement of securities described in this announcement was directed exclusively at persons who are “qualified investors” within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (Prospectus Regulation), as amended.
In the United Kingdom, the placement of securities described in this announcement was directed exclusively at persons who are “qualified investors” within the meaning of paragraph 15 of Schedule 1 to the Public Offers and Admissions to Trading Regulations 2024, and who are persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) or (iii) to whom it may otherwise be lawfully communicated (all such persons together being referred to as “Relevant Persons”). This announcement must not be acted on, or relied upon, by persons who are not Relevant Persons. Any investment or investment activity to which this announcement relates was available only to Relevant Persons and will be conducted only with Relevant Persons.
No action has been taken that would permit an offering or an acquisition of the securities or a distribution of this announcement in any jurisdiction where such action would be unlawful. Persons into whose possession this announcement comes are required to inform themselves about and to observe any such restrictions.

Contact:
Patrick Brenske, Management Board
Corporate Communications
E-Mail: ir@mph-ag.de


19.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: MPH Health Care AG
Grünauer Straße 5
12557 Berlin
Germany
Phone: 030 / 863 21 45 60
Fax: 030 / 863 21 45 69
E-mail: info@mph-ag.de
Internet: www.mph-ag.de
ISIN: DE000A289V03
WKN: A289V0
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt (Basic Board), Munich, Stuttgart, Tradegate BSX
LEI Code: 529900RLXP5HZXHVCT80
EQS News ID: 2439052

 
End of News EQS News Service

2439052  19.11.2026 CET/CEST

MPH Health Care AG announces placement of shares in M1 Kliniken AG

MPH Health Care AG

/ Key word(s): Disposal

MPH Health Care AG announces placement of shares in M1 Kliniken AG

19.11.2026 / 17:40 CET/CEST

The issuer is solely responsible for the content of this announcement.


MPH Health Care AG announces placement of shares in M1 Kliniken AG

The issuer is solely responsible for the content of this announcement.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION COULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PUBLICATION.
 

  • MPH Health Care AG (“MPH”) intends to sell up to 927,755 existing shares in M1 Kliniken AG (“M1”), representing approximately 5 per cent of the issued share capital, to institutional investors by way of an accelerated bookbuilding offering
  • Assuming full placement, MPH’s shareholding in M1 would decrease from approximately 66 per cent to approximately 61 per cent; MPH would thus remain the majority shareholder
  • The transaction is intended to increase the free float of M1, broaden the institutional shareholder base and strengthen the trading liquidity of the M1 share on a sustained basis

Berlin, 19 November 2026 – MPH Health Care AG (ISIN: DE000A289V03; “MPH”) intends to sell up to 927,755 existing no-par value bearer shares in M1 Kliniken AG (ISIN: DE000A0STSQ8; “M1”) to institutional investors by way of a private placement through an accelerated bookbuilding process. The final placement price and the number of shares actually placed will be determined in the course of the bookbuilding process.

“With the planned placement, we aim to broaden the institutional shareholder base and enhance the tradability of the M1 share. At the same time, our continued majority shareholding underlines our long-term commitment to M1 and to the further development of the company.”
–  Patrick Brenske, CEO of MPH Health Care AG

Assuming full placement, MPH would continue to hold approximately 11.4 million M1 shares and would thus remain the majority shareholder. The placement will be made exclusively from MPH’s existing shareholding.

M1 is the central holding within MPH’s portfolio and operates 59 clinics in ten countries under the M1 Med Beauty brand.

Transaction details

  • The bookbuilding is to commence immediately after publication of this announcement on 19 November 2026, following the close of trading on Xetra. The order book may be closed at short notice. The price and the placement size will be determined upon completion of the process; the results of the placement are expected to be announced on or around 19 November 2026.
  • The shares offered carry full dividend entitlement for the financial year 2026.
  • MPH entered into a three-month lock-up undertaking in respect of its M1 shares remaining after the placement, subject to customary exceptions.
  • Trade Date is scheduled for 20 November 2026 and Settlement Date is scheduled for 24 November 2026.
  • Cantor is acting as Sole Global Coordinator and Sole Bookrunner for the placement.

About MPH Health Care AG
MPH Health Care AG is a listed investment holding company headquartered in Berlin. Its focus is on the development and long-term value creation of equity investments, particularly in growth segments of the healthcare market. M1 Kliniken AG is MPH’s strategic core holding.

Investor Relations
MPH Health Care AG
Grünauer Straße 5
12557 Berlin
ir@mph-ag.de

Important Notice:
This announcement may not be released, published or distributed, directly or indirectly, in the United States of America (including its territories and possessions), Australia, Canada, Japan, South Africa or any other jurisdiction where such publication could be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons who are in possession of this announcement or other information referred to herein should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.
This announcement does not constitute an offer of, or a solicitation of an offer to purchase, securities of M1 Kliniken AG or of any of its subsidiaries in the United States of America, Germany or any other jurisdiction. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, an offer in any jurisdiction. The securities offered are not and have not been registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act. No public offering of securities is being made in the United States.
In member states of the European Economic Area, the placement of securities described in this announcement is directed exclusively at persons who are “qualified investors” within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (Prospectus Regulation), as amended.
In the United Kingdom, the placement of securities described in this announcement is directed exclusively at persons who are “qualified investors” within the meaning of paragraph 15 of Schedule 1 to the Public Offers and Admissions to Trading Regulations 2024, and who are persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) or (iii) to whom it may otherwise be lawfully communicated (all such persons together being referred to as “Relevant Persons”). This announcement must not be acted on, or relied upon, by persons who are not Relevant Persons. Any investment or investment activity to which this announcement relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.
No action has been taken that would permit an offering or an acquisition of the securities or a distribution of this announcement in any jurisdiction where such action would be unlawful. Persons into whose possession this announcement comes are required to inform themselves about and to observe any such restrictions.

Contact:
Patrick Brenske, Management Board
Corporate Communications
E-Mail: ir@mph-ag.de


19.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: MPH Health Care AG
Grünauer Straße 5
12557 Berlin
Germany
Phone: 030 / 863 21 45 60
Fax: 030 / 863 21 45 69
E-mail: info@mph-ag.de
Internet: www.mph-ag.de
ISIN: DE000A289V03
WKN: A289V0
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt (Basic Board), Munich, Stuttgart, Tradegate BSX
LEI Code: 529900RLXP5HZXHVCT80
EQS News ID: 2438898

 
End of News EQS News Service

2438898  19.11.2026 CET/CEST

Moody’s Ratings raises outlook for Fresenius to positive from stable

Fresenius SE & Co. KGaA

/ Key word(s): Rating

Moody’s Ratings raises outlook for Fresenius to positive from stable (news with additional features)

19.11.2026 / 13:45 CET/CEST

The issuer is solely responsible for the content of this announcement.


Moody’s Ratings, a globally recognized credit rating agency, has changed its credit outlook for Fresenius SE & Co. KGaA (XETR: FRE; OTCM: FSNUY) to positive from stable and affirmed the company’s Baa3 rating. In its ratings rationale, Moody’s acknowledged Fresenius’ improved growth trajectory and profitability as a result of the implementation of the #FutureFresenius strategy. Moody’s also highlighted the strengthening of Fresenius’ credit metrics and its strong liquidity.

“Moody’s is the third rating agency this year to revise its outlook for Fresenius to positive. These three revisions reflect the step-up in our financial profile. We have reduced our net leverage ratio to 2.5x while continuing to grow. We are using that financial flexibility to invest in innovation-led growth – with a clear focus on improving care for patients,” says Fresenius CFO Sara Hennicken.

Building on the structural improvements achieved through successful strategy execution, Fresenius continues to deliver healthy organic revenue growth, significant Core earnings per share (EPS) growth and improved returns. This progress has provided Fresenius with greater strategic flexibility to scale its growth vectors Medtech, Nutrition, and especially its Biopharma business through targeted investments. This includes the acquisition of the remaining 45% stake in mAbxience and a strategic development agreement with WuXi Biologics to expand Fresenius’ biosimilars pipeline.

With Moody’s latest revision, all three leading credit rating agencies have now raised their outlook for Fresenius to positive this year. Fresenius is rated investment grade by Moody’s (Baa3/positive), S&P (BBB/positive), and Fitch (BBB-/positive). The company remains committed to its investment grade rating and to its self-imposed target leverage range of 2.5 to 3.0x net debt/EBITDA1, which forms part of its financial framework.

1 Before special items. At average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures, including lease liabilities, including dividends from Fresenius Medical Care and Vitrea, net debt adjusted for the valuation effect of the exchangeable bond
 

# # #

Press Contact:
Timo Lindemann
Group Communications
Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
M +49 1511 5515324
timo.lindemann@fresenius.com
 

# # #

About Fresenius
Fresenius (XETR: FRE, OTCM: FSNUY) is a global, therapy-focused healthcare company dedicated to saving and improving human lives around the world. Through Fresenius Kabi and Fresenius Helios, the company delivers system-critical, innovative and affordable healthcare across the full continuum of care: Fresenius Kabi is a leading provider of lifesaving medicines, medical nutrition, and medical technologies for critically and chronically ill patients, reaching around 450 million people each year. Fresenius Helios is Europe’s largest private hospital operator, treating around 27 million patients annually.

With more than 178,000 employees and operating in more than 60 countries, Fresenius generated €22.6 billion in revenue in 2025.

For more information, visit www.fresenius.com and follow Fresenius on LinkedIn.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Wolfgang Kirsch

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Sara Hennicken, Dr. Marc-Alexander Mahl,
Dr. Michael Moser, Dr. Christian Pawlu 
Chairman of the Supervisory Board: Wolfgang Kirsch
 


Additional features:

File: 20261119_FSE_PressRelease_Moodys_Rating
File: Fresenius_Campus_Copyright
File: Fresenius_Flags_Copyright


19.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg v.d.H.
Germany
Phone: +49 (0)6172 608-97033
E-mail: ir-fre@fresenius.com
Internet: www.fresenius.com
ISIN: DE000FRE5EN2
WKN: FRE5EN
Indices: DAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Hamburg, Hanover, Stuttgart, Tradegate BSX; Luxembourg Stock Exchange
LEI Code: XDFJ0CYCOO1FXRFTQS51
EQS News ID: 2438128

 
End of News EQS News Service

2438128  19.11.2026 CET/CEST

Evotec and Bristol Myers Squibb Advance Strategic Protein Degradation Partnership with Second IND Acceptance

Evotec SE

/ Key word(s): Miscellaneous

Evotec and Bristol Myers Squibb Advance Strategic Protein Degradation Partnership with Second IND Acceptance

19.11.2026 / 07:30 CET/CEST

The issuer is solely responsible for the content of this announcement.


Evotec and Bristol Myers Squibb Advance Strategic Protein Degradation Partnership with Second IND Acceptance

  • FDA clearance expands partnered molecular glue pipeline
  • Achievement underscores productivity of the collaboration in molecular glue discovery and potential to address patient populations with high unmet need

Hamburg, Germany, November 19, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced that its strategic protein degradation partnership with Bristol Myers Squibb has received a second Investigational New Drug (IND) acceptance from the U.S. Food and Drug Administration (FDA). The first candidate produced under the partnership entered a Phase 1 clinical trial in advanced clear cell renal cell carcinoma in March 2026. The second accepted investigational drug candidate, a cereblon E3 ligase modulator (CELMoD), is expected to enter a Phase 1 clinical trial in 2027.

Initiated in 2018, the partnership combines Evotec’s high-performance multi-omics screening, AI-supported data analytics, and drug design capabilities with Bristol Myers Squibb’s industry-leading CELMoD agent library. This collaboration, expanded in 2022, continues to advance a pipeline of novel molecular glue degraders for high-value targets in oncology and beyond, translating scientific innovation into a growing therapeutic pipeline.

Dr. Joanna Holbrook, Chief Scientific Officer of Evotec, commented:

“The progression of a second molecular glue candidate to IND acceptance demonstrates the repeatability and productivity of our discovery platform. We are systematically translating complex biology into development candidates. This achievement reinforces the value of our longstanding collaboration with Bristol Myers Squibb and further strengthens our confidence in the platform’s potential to generate a growing pipeline of investigational drug candidates aimed at addressing substantial unmet medical needs.”

 

About molecular glue degraders

Conventional small molecule therapeutics act through drug-induced interference with protein activity. This limitation to agonistic or antagonistic functions renders about 90% of proteins “undruggable”. Also, conventional small molecules only work while they are actively binding to the receptor, which typically requires a treatment regimen consisting of one or even several carefully dosed medications every day.

Molecular glue degraders are compounds that induce interactions between an E3 ubiquitin ligase and a molecular target. The induced interaction results in ubiquitination and subsequent degradation of the recruited protein. By inducing neomorphic interactions between CRBN and substrate proteins, CELMoDs enable pharmacological modulation of proteins that may not be amenable to traditional inhibitor or agonist approaches, thereby expanding the potentially druggable proteome.

About Evotec’s strategic collaboration with Bristol Myers Squibb in molecular glues

In 2018, Evotec entered a long-term strategic drug discovery and development collaboration in the field of molecular glues with Celgene, now Bristol Myers Squibb. Bristol Myers Squibb is a leader in this field based on its unique library of CELMoD agents. The collaboration aims to discover and develop a leading pipeline of molecular glue degraders for a range of therapeutic indications leveraging all of Evotec’s proprietary PanOmics and PanHunter platforms as well as AI/ML-based drug discovery and development capabilities.

Evotec applies high-end proteomics and transcriptomics at industrial scale to profile and select promising drug candidates based on comprehensive cell biological profiles. Evotec’s leading PanOmics screening capabilities are delivering unmatched throughput. The selection of the most promising candidates for drug development is facilitated by Evotec’s PanOmics data analysis platform PanHunter. By integrating and analyzing these data sets, PanHunter supports the identification and advancement of the most promising CELMoDs into lead optimization.

 

About Evotec SE

Evotec is a life science company pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, Evotec accelerates the journey from concept to cure with greater speed, intelligence and precision. The company’s expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms including Molecular Patient Databases, PanOmics and induced pluripotent stem cell-based disease modeling. Through flexible partnering models tailored to customers’ needs, Evotec works with all Top 20 pharmaceutical companies, more than 800 biotechnology companies, academic institutions and other healthcare stakeholders. Evotec’s offerings range from standalone services to fully integrated research and development programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, the company is redefining biologics development and manufacturing to improve accessibility and affordability. With a portfolio of more than 100 proprietary research and development assets, most of which are co-owned, Evotec focuses on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology and immunology. Evotec’s global team of around 4,500 experts operates from sites in Europe and the United States, providing complementary technologies and services through a network of synergistic centers of excellence. Learn more at www.evotec.com and follow Evotec on LinkedIn and X at @Evotec.

Forward-Looking Statements

This announcement contains forward-looking statements concerning future events, including Evotec’s financial results, full-year 2026 outlook, expected commercial conversion, anticipated strategic partnership and milestone contributions, Horizon implementation, expected cost savings, liquidity, financial flexibility and future business performance. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of these words and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on information available to Evotec and on expectations and assumptions considered reasonable by the company at the time the statements were made. No assurance can be given that these expectations will prove correct. Forward-looking statements involve known and unknown risks and are based on assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond Evotec’s control. Evotec expressly disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement to reflect changes in expectations, events, conditions or circumstances, except as required by applicable law.

 

Investor Relations and Media Contact

Dr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.com


19.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Tradegate BSX; Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; Nasdaq
LEI Code: 529900F9KI6OYITO9B12
EQS News ID: 2438000

 
End of News EQS News Service

2438000  19.11.2026 CET/CEST

Medios Approves New Share Buyback Program

Medios AG

/ Key word(s): Share Buyback

Medios Approves New Share Buyback Program

18.11.2026 / 18:38 CET/CEST

The issuer is solely responsible for the content of this announcement.


Medios Approves New Share Buyback Program
  • Buyback of up to 1.5 million shares or a total value of up to 19 million euros
  • Immediate launch of the program, which will run for up to twelve months
  • Confidence in the Company’s medium- and long-term development

Berlin, November 18, 2026 – The Executive Board of Medios AG (“Medios,” ISIN: DE000A1MMCC8), a European pharmaceutical services provider, has approved a new share buyback program. The company plans to repurchase up to 1.5 million of its own shares on the stock exchange. This corresponds to a volume of up to 19 million euros, excluding incidental acquisition costs. The new share buyback program is scheduled to begin on November 19, 2026, and end no later than November 19, 2027.

Thomas Meier, CEO of Medios AG: “With this share buyback, we are consistently implementing the capital allocation strategy we presented at our Capital Markets Day in late September 2026. This measure also underscores our confidence in the strength of our business model, our financial performance, and the sustainable growth potential of our strategy.”

Share buyback program is part of the “Medios Next Level” strategy
As part of the “Medios Next Level” strategy unveiled in September, the company is targeting consolidated revenue of approximately 3.1 billion euros and an adjusted EBITDA margin1 of approximately 5.5% for fiscal year 2031.

Medios had also announced that it would use share buybacks as its preferred instrument for returning capital to its shareholders. The buyback that has now been approved underscores – in addition to the Group’s profitable growth – Medios’ commitment to creating sustainable value for its shareholders.

The new share buyback program also fits into this context. The repurchased shares can be used flexibly within the scope of the authorization granted by the Annual Shareholders’ Meeting, for example, as “acquisition currency” in corporate acquisitions, for employee stock ownership plans, or for stock-based compensation plans.

Following the successful first share buyback program in fiscal year 2025, Medios will shortly retire the treasury shares acquired under that program – which currently total 986,362 shares (3.9% of the share capital) – and reduce the share capital accordingly. This will permanently reduce the number of outstanding shares with the aim of strengthening the long-term value per share for the remaining shareholders.
1 To improve transparency regarding its financial results, Medios will switch from “EBITDA pre” to a newly defined “EBITDA adjusted” starting in fiscal year 2027. Going forward, adjustments will be limited to two clearly defined categories: M&A expenses and restructuring costs.

About Medios AG
Medios is a European pharmaceutical services group with two operating segments –Specialty Pharma Supply and Compounding – and operates in Germany, the Netherlands, Belgium, and Spain. Working closely with pharmacies, specialist medical practices, and pharmaceutical companies, Medios combines pharmaceutical expertise, manufacturing capabilities, and smart services to enable reliable and efficient access to innovative and individualized therapies. The focus is on patients with complex and chronic conditions, including cancer, autoimmune diseases, and neurological and metabolic disorders.

Medios AG is Germany’s first listed specialty pharmaceutical Company. The shares (ISIN: DE000A1MMCC8) are listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and are included in the SDAX selection index.
www.medios.group

Kontakt
Katrin Neuffer
Director Investor Relations & Communications
Medios AG
Heidestraße 9 | 10557 Berlin
T +49 30 232 566 800
ir@medios.group
www.medios.group

 


18.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Medios AG
Heidestraße 9
10557 Berlin
Germany
Phone: +49 30 232 566 – 800
Fax: +49 30 232 566 – 801
E-mail: ir@medios.group
Internet: www.medios.group
ISIN: DE000A1MMCC8
WKN: A1MMCC
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX
LEI Code: 391200Z7Z09IHDBT2L23
EQS News ID: 2437942

 
End of News EQS News Service

2437942  18.11.2026 CET/CEST

Medios AG: Medios AG adopts public share buyback program

Medios AG / Key word(s): Capital measures / Share buybacks

Medios AG: Medios AG adopts public share buyback program

18-Nov-2026 / 18:33 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.

The issuer is solely responsible for the content of this announcement.


Berlin, November 18, 2026 – Today, the management board of Medios AG (“Medios”) decided to adopt a public buyback program for up to 1,500,000 shares of Medios (amounting to approx. ca. 5.88% of the share capital in the amount of EUR 25,505,723.00) via the stock exchange. The volume of the buyback program amounts to up to EUR 19 million (excluding incidental purchasing costs).

The buyback program is set to start tomorrow and extend until no later than November 19, 2027.

Thereby, Medios makes use of the authorization granted by the annual shareholders’ meeting of June 10, 2026, according to which until June 9, 2031, Medios may buy back shares totaling up to 10% of either the registered share capital at the time of the resolution or, if this amount is lower, the registered share capital at the time this authorization is exercised. No treasury shares have been purchased using this authorization so far. Medios currently holds 986,362 treasury shares from prior purchases (approx. 3.87% of the registered share capital). These 986,362 treasury shares are to be redeemed soon, and the share capital is to be reduced accordingly.

The shares to be repurchased may be used for any purpose permitted under the authorization granted by the annual shareholders’ meeting on June 10, 2026. These shares may also be redeemed.

The buyback program will be conducted in accordance with the provisions of Regulation (EU) No. 596/2014 and Commission Delegated Regulation (EU) 2016/1052. Further details will be published prior to the start of the buyback program. Medios reserves the right to terminate the buyback program at any time.

Disclosing person: Stefan Bauerreis, member of the management board (CFO)

End of Inside Information

Contact
Katrin Neuffer
Director Investor Relations & Communications
Medios AG
Heidestraße 9 | 10557 Berlin
T +49 30 232 566 800
ir@medios.group
www.medios.ag
 

End of Inside Information


18-Nov-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Medios AG
Heidestraße 9
10557 Berlin
Germany
Phone: +49 30 232 566 – 800
Fax: +49 30 232 566 – 801
E-mail: ir@medios.group
Internet: www.medios.group
ISIN: DE000A1MMCC8
WKN: A1MMCC
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX
LEI Code: 391200Z7Z09IHDBT2L23
EQS News ID: 2437902

 
End of Announcement EQS News Service

2437902  18-Nov-2026 CET/CEST

Drägerwerk AG & Co. KGaA: Dräger presents Ambition 2030: EUR 4.5 billion in net sales and a 10 to 12 percent EBIT margin

Drägerwerk AG & Co. KGaA

/ Key word(s): Capital Markets Day

Drägerwerk AG & Co. KGaA: Dräger presents Ambition 2030: EUR 4.5 billion in net sales and a 10 to 12 percent EBIT margin

18.11.2026 / 10:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


Dräger presents Ambition 2030: EUR 4.5 billion in net sales and a 10 to 12 percent EBIT margin

  • Significant increase in net sales and improvement in margins targeted by 2030
  • Profitable growth in both divisions
  • Medical division: growth through integrated solutions and recurring revenues
  • Safety division: expansion of business in selected growth markets
  • Strong balance sheet, disciplined capital allocation, and attractive dividend

Lübeck – Drägerwerk AG & Co. KGaA is presenting its Ambition 2030 today at its first Capital Markets Day in Lübeck. Accordingly, Dräger is aiming for a medium-term increase in net sales of EUR 1 billion to around EUR 4.5 billion (2025: EUR 3.5 billion). The medical and safety divisions should each grow by around EUR 500 million. Earnings before interest and taxes (EBIT) are also supposed to rise significantly. The EBIT margin should reach 10 to 12 percent by 2030 (2025: 6.7 percent).

“With our Technology for Life, we create tangible value for our customers and sustainable value for our stakeholders. Our Ambition 2030 shows how we intend to build further profitable growth on this,” says Stefan Dräger, Chairman of the Executive Board of Drägerwerk Verwaltungs AG. “In the medical division, we are focusing on integrated solutions and recurring revenue. In the safety division, we are expanding our business in selected growth markets. At the same time, we want to increase our productivity and strengthen our financial position.”

Improving acute care in the medical division
The medical division plans to continue improving acute care. To this end, its strong position in life-sustaining systems will be expanded. Further growth will come from integrated solutions and recurring revenues from the installed base of equipment. Patient monitoring will also be expanded. Regionally, the medical division is focusing in particular on growth in the U.S. and Asia-Pacific. Europe remains a strong base. Net sales growth and efficiency measures are expected to increase profitability. By 2030, the medical division is targeting net sales of around EUR 2.5 billion and an EBIT margin of 7 to 9 percent.

Targeted scaling in the safety division’s focus markets
The safety division aims to scale profitable growth in a targeted manner. The focus is on four growth markets: U.S. fire departments, defense, maritime applications as well as energy transition and cleantech. Technology and innovation are intended to strengthen the offering. The plan also includes expanding market access in the U.S. and the Asia-Pacific region and leveraging Europe as a strong base. Further growth in net sales and higher productivity are intended to support profitability. By 2030, the division is aiming at net sales of around EUR 2.0 billion and an EBIT margin of 14 to 16 percent.

Strong balance sheet, disciplined capital allocation, and attractive dividend
The improvement in margins is expected to result from a higher gross margin and a below-proportionate increase in functional expenses. To this end, Dräger intends, among other things, to improve pricing, optimize direct costs, and increase productivity. More efficient development processes and improvements in sales and administration are expected to make further contributions. At the same time, Dräger wants to safeguard its strong balance sheet and high equity ratio. In capital allocation, financial stability and high-return organic investments take priority. Selective acquisitions can complement the strategy. The dividend policy remains attractive. Dräger intends to continue distributing at least 30 percent of net profit to its shareholders. This would lead to double-digit dividend growth in the coming years.

Sustainability supports Ambition 2030
The sustainability strategy is also an important part of Ambition 2030. Dräger’s goal is to reduce Scope 1 and Scope 2 emissions by more than 30 percent by 2030 compared to the base year of 2024 and to achieve “net zero” by 2045. Dräger also wants to help its customers reduce environmental impacts and operating costs with resource-efficient products and solutions. This customer benefit is intended to strengthen the Company’s market position and open up additional growth opportunities. The combination of sustainability and profitability supports Ambition 2030.

Live broadcast of the Capital Markets Day
The Capital Markets Day will be broadcast live from 10:15 a.m. to approximately 2:30 p.m. and can be viewed online via Dräger’s Investor Relations website. A recording of the event and the Executive Board presentations will be made available afterward on the Company’s Investor Relations website (https://www.draeger.com/en-us_us/Investor-Relations/capital-markets-day).

Further information is available at www.draeger.com.

Disclaimer
This press release contains statements on the future development of Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to date. They were compiled to the best of the company’s knowledge. Dräger does not provide any warranty nor assume any responsibility for the future developments and results described above. These are dependent on a number of factors. They entail various risks and contingencies outside of the company’s influence and are based on assumptions which could prove to be incorrect. Dräger does not assume any responsibility for updating the forward-looking statements contained in this release. This does not infringe any legal stipulations on the adjustment of forecasts. Information on the financial indicators used (incl. alternative performance measures) can be found on our corporate website www.draeger.com in our Investor Relations section.

 

 


18.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Drägerwerk AG & Co. KGaA
Moislinger Allee 53-55
23558 Lübeck
Germany
Phone: +49 (0)451 882-0
Fax: +49 (0)451 882-2080
E-mail: info@draeger.com
Internet: www.draeger.com
ISIN: DE0005550602, DE0005550636 (Vorzugsaktien)
WKN: 555060, 555063 (Vorzugsaktien)
Indices: SDAX, TecDax
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX; London, Aquis, Stockholm, BX, SIX, Vienna Stock Exchange
LEI Code: 5493005UFVHY0PPNKD75
EQS News ID: 2436204

 
End of News EQS News Service

2436204  18.11.2026 CET/CEST

M1 Kliniken AG’s nine-month Beauty EBIT rises 35.5% to EUR 28.6 million

M1 Kliniken AG

/ Key word(s): 9 Month figures/Change in Forecast

M1 Kliniken AG’s nine-month Beauty EBIT rises 35.5% to EUR 28.6 million

18.11.2026 / 08:30 CET/CEST

The issuer is solely responsible for the content of this announcement.


M1 Kliniken AG’s nine-month Beauty EBIT rises 35.5% to EUR 28.6 million

Berlin, 18 November 2026 – M1 Kliniken AG (ISIN: DE000A0STSQ8) reported EBIT of EUR 28.6 million in its Beauty segment for the first nine months of 2026. This already exceeds the EUR 28.3 million the segment earned in the whole of 2025. The EBIT margin rose to 33.0% from 27.1% in the same period last year.

Beauty segment delivers further growth and higher profitability

  • Revenue: up 11.3% to EUR 86.6 million (9M 2025: EUR 77.8 million)
  • EBIT: up 35.5% to EUR 28.6 million (9M 2025: EUR 21.1 million)
  • EBIT margin: 33.0% (9M 2025: 27.1%)

EBIT grew even faster in the third quarter:

  • Revenue: up 11.7% to EUR 29.7 million (Q3 2025: EUR 26.6 million)
  • EBIT: up 63.9% to EUR 10.0 million (Q3 2025: EUR 6.1 million)
  • EBIT margin: 33.7% (Q3 2025: 22.9%)

Group earnings and margins rise year on year

  • Group revenue: EUR 106.3 million (9M 2025: EUR 274.3 million)
  • EBITDA: up 1.5% to EUR 28.7 million (9M 2025: EUR 28.2 million)
  • EBIT: up 4.6% to EUR 25.6 million (9M 2025: EUR 24.5 million)
  • EBIT margin: 24.1% (9M 2025: 8.9%)
  • Adjusted EBIT: up 21.1% to EUR 29.7 million (9M 2025: EUR 24.5 million)
  • EBT: up 7.0% to EUR 26.1 million (9M 2025: EUR 24.4 million)
  • Earnings per share: up 5.6% to EUR 0.91 (9M 2025: EUR 0.86)

The Group figures are only partly comparable with the prior year. M1 Aesthetics AG (formerly HAEMATO AG), in which the Group holds an 85% stake, sold HAEMATO Pharm GmbH with effect from the close of 31 January 2026. As a result, the figures include the Trading segment for only one month, compared with nine months in the prior-year period. This accounts for the entire decline in Group revenue.

Group EBIT includes a one-off non-cash charge of EUR 4.1 million from the deconsolidation. Adjusted for this charge, EBIT reached EUR 29.7 million, up 21.1% year on year. Third-quarter earnings per share were EUR 0.38 (Q3 2025: EUR 0.23).

Group completes planned exit from the Trading segment

  • Revenue: EUR 19.7 million (9M 2025: EUR 196.5 million)
  • EBIT: EUR −3.0 million (9M 2025: EUR 3.4 million)

All Trading segment revenue was generated in January 2026, the final month before the sale. Segment EBIT includes the EUR 4.1 million deconsolidation charge. Since the sale, the Group has focused exclusively on the Beauty segment.

Outlook

The Management Board has raised its medium-term margin target. By 2029, the Group aims to generate revenue of EUR 200 million to EUR 300 million in the Beauty segment at a sustainable EBIT margin of at least 25% (previously at least 20%). To reach these targets, M1 plans to open further clinics in Germany and abroad. The Heilbronn clinic is scheduled to open on 1 December 2026, bringing the network to 60 clinics. Further openings are planned for 2027. In the longer term, the Group aims to establish M1 Med Beauty as the world’s leading brand in aesthetic medicine.

The Company plans to move its listing from the Open Market to the Prime Standard of the Frankfurt Stock Exchange in 2027. It remains committed to its stable dividend policy. The Company announced the higher margin target and the planned move in an ad hoc announcement yesterday evening.

“Our business model scales. Both in Germany and abroad, we are carrying out more treatments and expanding our medical capacity,” said Attila Strauss, CEO of M1 Kliniken AG. “Moving to the Prime Standard will make our shares accessible to a broader range of institutional investors.”

About M1 Kliniken AG

M1 Kliniken AG is the leading fully integrated provider of aesthetic medical services in Europe and Australia. Under the M1 Med Beauty brand, the Group operates 59 clinics in ten countries using a focused, highly standardised and scalable business model. All treatments are performed by qualified doctors to the same high quality standards and are offered at market-leading prices. The Group has pursued international expansion since the end of 2018 to support further growth and strengthen its global market position. In Berlin, the Group operates M1 Schlossklinik, one of Europe’s largest and most modern clinics for aesthetic plastic surgery. The clinic has four operating theatres and 35 beds.

Contact:
M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
T: +49 (0)30 347 47 44 14
M: ir@m1-kliniken.de


18.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
Germany
Phone: +49 (0)30 347 47 44 14
Fax: +49 (0)30 347 47 44 17
E-mail: ir@m1-kliniken.de
Internet: https://www.m1-kliniken.de
ISIN: DE000A0STSQ8
WKN: A0STSQ
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX
LEI Code: 529900W697S31A26WT02
EQS News ID: 2437242

 
End of News EQS News Service

2437242  18.11.2026 CET/CEST

Ellipses Pharma explores a London Stock Exchange listing opportunity

Ellipses Pharma explores a London Stock Exchange listing opportunity




Ellipses Pharma explores a London Stock Exchange listing opportunity

LONDON–(BUSINESS WIRE)–Ellipses Pharma Limited (“Ellipses”) the London-based global oncology drug development company with a pipeline of innovative programmes, today announced that the Company is exploring a listing opportunity on the main market of the London Stock Exchange.


Ellipses has signed a non-binding Memorandum of Understanding (“MoU”) with Wolfram Resources Plc (LSE: WFR) (“Wolfram”) a main market listed special purpose acquisition company whose ordinary shares are traded on the Equity Shares (Shell Companies) listing category. The MoU is intended to result in a reverse takeover through the proposed acquisition of the entire issued share capital of Ellipses by Wolfram and the re-listing of the enlarged group on the Main Market on the Equity Shares (Commercial Companies) category.

Since its establishment in 2017, Ellipses has focused on identifying, acquiring and advancing promising oncology assets through clinical development. The proposed transaction with Wolfram provides a potential public market platform from which to support the continued development of its portfolio, broaden access to capital and create opportunities for long-term value generation for its shareholders.

Ellipses’ portfolio spans multiple clinical-stage programmes, with trial sites across the United States, Europe and Asia Pacific. This includes EP0031 (lunbotinib), a next-generation selective RET inhibitor in Phase 2 development for RET-altered non-small cell lung cancer, partnered with Kelun-Biotech, and EP0062 (vosilasarm), an oral selective androgen receptor modulator in Phase 2 development in ER+/HER2- breast cancer.

Proposed Transaction

The consideration for the proposed transaction with Wolfram is expected to be satisfied through the issue of new ordinary shares in Wolfram, with final terms to be agreed following due diligence. An equity fundraising is also expected to be undertaken in conjunction with the Proposed Transaction.

Ellipses and Wolfram will now commence a period of due diligence and work towards agreeing definitive transaction documentation and final terms, with completion currently targeted for early 2027. There can be no certainty that the Proposed Transaction will proceed or as to the final terms on which it may proceed.

Professor Sir Chris Evans OBE, Founder and Chair of Ellipses Pharma, said:

“Our company has been focused resolutely on the development of promising drug candidates and the progress made with our pipeline, including encouraging results from our clinical trials for both EP0031 and EP0062, which indicates that this is now the optimal time to move towards a public listing. We also see our main market listing as a shot in the arm for the UK Life Sciences sector which has a great scientific pedigree.

“The proposed transaction with Wolfram will accelerate Ellipses’ plan to deliver the next stage of our evolution as a public company. Opting to list through a reverse takeover process has recently become more common in the Life Sciences sector and will enable us to raise additional capital from public company investors. This will drive progress within our portfolio, broaden access to capital and allow our current shareholders to realise growth in the longer term. We look forward to working with the Wolfram team to deliver the transaction.

Graeme Muir, Executive Director of Wolfram Resources Plc, said:

“We are excited to be working with such a strong management team that brings with it years of experience and a proven track record. We now move to detailed due diligence, and we believe this transaction can deliver real value for Wolfram shareholders.”

Further information

Further information about Ellipses Pharma is available at www.ellipses.life.

Contacts

media@ellipses.life
Ramsay Smith, Media House International

+44 (0) 7788 414856

Verfora acquires majority stake in distribution partner Qpharma

Verfora is acquiring a majority stake in the Polish pharmaceutical distributor Qpharma. With the acquisition of 51% of the shares, Verfora is expanding its distribution network to include a long-standing distribution partner and thus an established distribution platform. At the same time, the company is gaining an important partner along its own value chain and thus, alongside Austria, a second distribution network in Europe. The combination of strong brands, marketing expertise and local distribution know-how creates additional development opportunities for its existing consumer healthcare business.

Established distribution platform

Qpharma is a family-run company based in Poland that has been active in the healthcare market for over 20 years and generated sales in the low double-digit million euro range. The company specialises in marketing, promotion and distribution of prescription-only drugs, OTC products and dietary supplements. Qpharma has exclusive distribution rights for various brands in Poland, the Czech Republic and Slovakia.

Qpharma has built up an established market position in Eastern Europe and has long-standing customer relationships as well as extensive experience in marketing and distribution of healthcare products. The company has been working with Verfora for many years and is responsible for the distribution of various Verfora products, including Perskindol in Poland and the Czech Republic and, since 2025, Padma products in Poland.

Acquisition of a long-standing partner

The acquisition brings together Verfora’s brand and marketing expertise with Qpharma’s established distribution platform and expands Verfora’s value chain. Qpharma’s attractive distribution licences also offer further development potential. Following the acquisition, Qpharma will continue to be managed by the current CEO, Zbyszek Czop, and developed together with Verfora.

“Qpharma has been an important partner for our brands for many years with an excellent understanding of our products, quality standards and its customers’ needs. With this acquisition, we are further developing a successful collaboration and creating the conditions to make even better use of our combined potential,” says Stefan Wälti, CEO of Verfora.

Completion of the transaction is subject to regulatory approvals. The parties have agreed not to disclose the sale price.